If you’ve been diagnosed with gastroenteropancreatic neuroendocrine tumors, or GEP-NETs (tumors that form in the gastrointestinal tract and release hormones), you may experience carcinoid syndrome.
It’s important to know about carcinoid syndrome because it may affect your treatment options for GEP-NETs, according to Kimberly Perez, MD, Medical Oncologist at the Dana-Farber Cancer Institute in Boston.
What is carcinoid syndrome?
About 10 percent of people with GEP-NETs develop carcinoid syndrome. It’s a group of symptoms that occur due to the cancer cells releasing extra hormones, including serotonin.
These symptoms may include:
Diarrhea
Flushing
Stomach pain
Racing heart
Low appetite
Swelling
Carcinoid syndrome is more common in people who have GEP-NETs in their small intestines. The risk may also be elevated when the cancer metastasizes (spreads) to other organs, such as the liver.
What happens if you are experiencing carcinoid syndrome?
If you’re experiencing symptoms of carcinoid syndrome, talk to your care team.
“Based on the symptoms that you describe, they should be able to make the diagnosis of carcinoid syndrome purely based on your conversation,” says Perez.
Your care team may also decide to measure the hormone levels in your blood in order to make or confirm a diagnosis.
Carcinoid syndrome is treated with medicine called somatostatin analogs. This medication attaches to the tumor cell and prevents it from releasing the extra hormones, which may help manage the symptoms.
You may also receive other treatments, including chemotherapy, targeted therapy, or radioligand therapy, if you’re eligible. The right option for you depends on many factors, including if or where the cancer has spread to other locations.
That’s why it’s important to let your care team know if you’re having symptoms so that they know which treatments to give you.
Kimberly Perez, MD, is a Medical Oncologist at the Dana Farber Cancer Institute in Boston, MA.
References
American Cancer Society. (2018). Signs and symptoms of gastrointestinal carcinoid tumors.
American Cancer Society. (2018). Treatment of gastrointestinal carcinoid tumors, by extent of disease.
American Cancer Society. (2020). Tests for gastrointestinal carcinoid tumors.
Chan, J. A., et al. (2023). Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion. UpToDate.
Cives, M., et al. (2018). Gastroenteropancreatic neuroendocrine tumors. CA: A Cancer Journal for Clinicians.
Pandit, S., et al. (2023). Carcinoid syndrome. StatPearls.
Why trust our experts?











